[Cardiac amyloidosis].
Poullot. Elsa E; Oghina. Silvia S; Kalsoum. Sarah S; Damy. Thibaud T
Key Findings
- Cardiac amyloidosis is most often caused by transthyretin or light‑chain proteins.
- Accurate typing of the amyloid protein is crucial for choosing the right treatment.
- Recent advances in diagnostics and targeted drugs have markedly improved prognosis.
Practical Outcomes
- For biohackers, the paper offers no direct protocols or supplement guidance. It mainly informs about a serious heart condition and the importance of medical diagnosis and specialized therapy, which are outside typical self‑experimentation scopes.
Summary
The article explains that certain proteins can build up in the heart, causing a condition called cardiac amyloidosis. It describes the main types (transthyretin and light‑chain), how doctors spot the disease, and the newer medicines that can improve outcomes, especially when the exact protein type is identified.
Abstract
Different types of amyloid deposits involve the heart. Transthyretin and light chain amyloidosis are the most frequent. Diagnostic performance, typing and treatments have improved in the last decade, and prognosis of cardiac amyloidosis is now significantly better thanks to targeted therapies. In this article, we will describe the clinical manifestations of cardiac amyloidosis, the diagnostic approach and detail the characteristics and specific treatments of the most frequent types of cardiac amyloidosis. We will focus on the histopathological aspects, especially on the importance of amyloid typing.
Study Information
pubmed
2021
2021-01-06T00:00:00.000Z
10.1016/j.annpat.2020.11.010
2